Abstract | OBJECTIVE: METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 94 primary endometrial carcinomas were stained for A-LAP, AngII, AT1R and VEGF using each antibody. Disease-free survival (DFS) and other clinicopathologic characteristics were analyzed according to the intensity of each staining. RESULTS: Of 94 cases, 91 (96.8%) showed specific A-LAP immunostaining. A-LAP expression demonstrated negative correlations with myometrial invasion (p = 0.01) and vascular infiltration (p = 0.01). Of 94 cases, 77 (81.9%) showed specific AngII immunostaining. We found a positive correlation between AngII expression and surgical stage (p = 0.01). Of 94 cases, 56 (59.6%) showed specific AT1R immunostaining and 73 (77.7%) specific VEGF immunostaining. We found a positive correlation between VEGF expression and lymph node metastasis (p = 0.05). AngII and AT1R expression predicted a significantly poorer prognosis. Contrarily, A-LAP expression indicated a significantly more favorable prognosis in endometrial endometrioid adenocarcinoma patients. Multivariate analysis demonstrated that A-LAP expression (odds ratio, 0.12; 95% confidence interval, 0.025-0.618; p = 0.01) was an independent prognostic factor. CONCLUSIONS: In this study, we demonstrated the existence of local RAS and A-LAP in endometrial endometrioid adenocarcinoma as prognostic predictors of clinical outcome. These findings suggest that the assessment of RAS and A-LAP status provides clinically useful prognostic information in patients with endometrial carcinoma.
|
Authors | Kiyosumi Shibata, Fumitaka Kikkawa, Yayoi Mizokami, Hiroaki Kajiyama, Kazuhiko Ino, Seiji Nomura, Shigehiko Mizutani |
Journal | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
(Tumour Biol)
2005 Jan-Feb
Vol. 26
Issue 1
Pg. 9-16
ISSN: 1010-4283 [Print] Netherlands |
PMID | 15741767
(Publication Type: Journal Article)
|
Chemical References |
- Receptor, Angiotensin, Type 1
- Vascular Endothelial Growth Factors
- Angiotensin II
- Leucyl Aminopeptidase
|
Topics |
- Adipocytes
(enzymology)
- Angiotensin II
(analysis, biosynthesis)
- Carcinoma, Endometrioid
(blood supply, metabolism, therapy)
- Disease-Free Survival
- Endometrial Neoplasms
(blood supply, metabolism, therapy)
- Female
- Humans
- Leucyl Aminopeptidase
(analysis, biosynthesis, genetics)
- Lymphatic Metastasis
- Middle Aged
- Neovascularization, Pathologic
- Receptor, Angiotensin, Type 1
(analysis, biosynthesis)
- Renin-Angiotensin System
- Vascular Endothelial Growth Factors
(analysis, biosynthesis)
|